LOTUSEYE112.50

Lotus Eye Hospital and Institute Limited

· Pharma & Health
AnnualQuarterly₹ CrorePeersGPTHEALTHGKSLSHALBYINDRAMEDCOARTEMISMEDDRAGARWQKMCSHILKOVAIMcap ₹234 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Revenue from Operations48.249.653.7
Other Income1.31.31.2
Total Income49.550.954.9
Expenses
+ Cost of Materials Consumed8.48.28.5
+ Purchases of Stock-in-Trade7.17.48.1
+ Changes in Inventories-0.2-0.2-0.0
+ Employee Benefit Expense9.811.612.2
+ Finance Costs0.10.40.9
+ Depreciation & Amortisation3.73.03.7
+ Other Expenses16.519.121.5
Total Expenses45.549.554.9
EBITDA6.53.43.4
EBIT2.80.4-0.4
Profit
PBT before Exceptional Items4.01.4-0.0
+ Exceptional Items0.00.0-0.0
Pretax Income4.01.4-0.1
+ Current Tax1.00.40.0
+ Deferred Tax0.10.3-0.1
Tax Expense1.10.6-0.1
Net Income2.90.70.1
+ Net Income — Continuing Ops2.90.70.1
+ Other Comprehensive Income-0.0-0.10.1
Total Comprehensive Income2.90.60.1
Per Share
Basic EPS1.400.360.04
Diluted EPS1.400.360.04
Other Comprehensive Income — detail
+ Other Comprehensive Income-0.10.1
+ Items NOT to be Reclassified to P&L-0.1-0.20.1
+ Tax on Items NOT to be Reclassified-0.10.0
+ Tax on Items NOT to be Reclassified — alt tag-0.0
Per Share — as-filed variants
Basic EPS — Continuing Operations1.400.360.04
Diluted EPS — Continuing Operations1.400.360.04
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit32.934.137.1
Gross Margin %68.2268.8169.02
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)4.01.4-0.0
− Exceptional Items (reconciliation)0.00.0-0.0
Net Income Adj (tax-effected)2.90.70.1
EPS Adj1.400.360.04
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value10.0010.0010.00
Paid Up Equity Capital20.820.820.8
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.